Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionMode of deathEjection fractionCause-specific deathHeart failureCardiovascular deathNew York Heart Association class IIGuideline-directed medical therapyStudy case report formsSudden deathVentricular ejection fractionRate of sudden deathAssociated with lower ratesCox regression modelsImproved ejection fractionRandomized clinical trialsReduce cardiovascular mortalityCase report formsEnd-point committeeClinical end point committeePost hoc analysisDapagliflozin EvaluationIV symptomsHFimpEFMedical therapy